AIToday
AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIPublished: Nov 19, 2026, 06:31 JST

Pfizer CEO Albert Bourla: China, not Lilly, is top rival by 2030

Send on LINE
Pfizer CEO Albert Bourla: China, not Lilly, is top rival by 2030

3 Key Points

  1. What happened

    At the Jefferies Global Healthcare Conference in London, Pfizer CEO Albert Bourla said Chinese biotech will be his major competition by 2030, not AstraZeneca or Lilly, citing China's 3x, 4x speed and half the cost.

  2. Why it matters

    Bourla said Pfizer needs AI to deliver the same efficiencies, calling it the biggest lever to build a future Pfizer productive at 3x, 4x the speed and half the cost.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

Bourla's remarks at the Jefferies conference mark a shift in how Pfizer frames its competitive set. Rather than measuring itself against AstraZeneca or Lilly — companies he described as "pretty much one category" — Bourla pointed to an entire nation with a stated ambition to become a global biotech player. China's latest five-year plan sets a concrete target: Chinese companies discovering a third of all global blockbusters by 2030, a goal experts say the country is on track to hit.

The competitive gap Bourla highlights is not just about cost but about pace. He said Chinese companies are coming at half the cost and 3x, 4x the speed, a combination that traditional pharma operating models struggle to match. That framing makes AI less of an innovation project and more of a survival tool — Bourla called it the biggest lever to build a Pfizer productive at those same levels.

Once those efficiencies are achieved, Bourla said companies will face a strategic choice: do more with the same, do more with less, or do less with less. That question, left open, suggests the industry's AI payoff may reshape not just costs but the scope of what drugmakers choose to pursue.

FAQ
What did Bourla say about AI's role at Pfizer?
Bourla called AI the biggest lever to build the Pfizer of the future, one that is productive at 3x, 4x the speed and half the cost. He sees AI impacting all parts of Pfizer's business, including sales and marketing.
What is China's stated goal for biotech?
China's latest five-year plan sets a goal of Chinese companies discovering a third of all global blockbusters by 2030.
How does Bourla describe the cost and speed gap?
He said Chinese companies are coming at half the cost and 3x, 4x the speed.
Top Companies AIRead Original Article
Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleVisa expands Agentic Ready to 140+ participants